Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China
Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao, Jisheng Li · 2026
Read Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China by Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao, Jisheng Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400920.txt.
Description
Yihong Guo and a large team weigh, in 2026, the cost-effectiveness of two combination therapies for advanced lung cancer with EGFR mutations, from United States and Chinese perspectives. Two landmark trials had shown adding chemotherapy to osimertinib, or pairing two newer drugs, beats osimertinib alone. Payers must judge whether the gains justify the prices.
A survival model projected costs, life years and quality-adjusted life years over ten years. Against osimertinib alone, the chemotherapy combination cost far less per quality year gained than the dual-drug regimen in both countries, though both exceeded typical United States thresholds. Drug prices and quality-of-life values drove the results most. A patient assistance scenario for China was also modeled.
Catalog record
| CREATOR | Yihong Guo, Shixian Liu, Chuang Yang, Chengjun Wang, Rongyu Zhang, Yunfei Wang, Yanan Song, Mingfei Liu, Ruolin Zhang, Tiantian Xuan, Wen Zhao, Jisheng Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29850 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |